Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events
Open Access
- 27 September 2011
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (2), 504-512
- https://doi.org/10.1002/art.33340
Abstract
Objective To define the antiphospholipid score (aPL‐S) by testing multiple antiphospholipid antibodies (aPL) and to evaluate its efficacy for the diagnosis of antiphospholipid syndrome (APS) and predictive value for thrombosis. Methods This study comprised 2 independent sets of patients with autoimmune diseases. In the first set of patients (n = 233), the aPL profiles were analyzed. Five clotting assays for testing lupus anticoagulant and 6 enzyme‐linked immunosorbent assays (IgG/IgM anticardiolipin antibodies, IgG/IgM anti–β2‐glycoprotein I, and IgG/IgM phosphatidylserine‐dependent antiprothrombin antibodies) were included. The association of the aPL‐S with a history of thrombosis/pregnancy morbidity was assessed. In the second set of patients (n = 411), the predictive value of the aPL‐S for thrombosis was evaluated retrospectively. Two hundred ninety‐six of these patients were followed up for >2 years. The relationship between the aPL‐S and the risk of developing thrombosis was analyzed. Results In the first set of patients, the aPL‐S was higher in those with thrombosis/pregnancy morbidity than in those without manifestations of APS (P < 0.00001). For the aPL‐S, the area under the receiver operating characteristic curve value was 0.752. In the second set of patients, new thromboses developed in 32 patients. The odds ratio (OR) for thrombosis in patients with an aPL‐S of ≥30 was 5.27 (95% confidence interval [95% CI] 2.32–11.95, P < 0.0001). By multivariate analysis, an aPL‐S of ≥30 appeared to be an independent risk factor for thrombosis (hazard ratio 3.144 [95% CI 1.383–7.150], P = 0.006). Conclusion The aPL‐S is a useful quantitative index for diagnosing APS and may be a predictive marker for thrombosis in autoimmune diseases.Keywords
This publication has 43 references indexed in Scilit:
- Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practiceLupus, 2010
- Antiphospholipid antibodies and malignanciesAutoimmunity Reviews, 2010
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- A Quarter of a Century in Anticardiolipin Antibody Testing and Attempted Standardization Has Led Us to Here, which Is?Seminars in Thrombosis and Hemostasis, 2008
- Invitation to a debate on the serological criteria that define the antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2008
- Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samplesJournal of Thrombosis and Haemostasis, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti- 2Glycoprotein I antibodiesInternational Immunology, 2004
- Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndromeRheumatology, 1996
- β2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipinThe Lancet, 1990